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Abstract
Clear cell renal cell carcinoma (ccRCC) represents the most common type of
kidney cancer with high mortality in its advanced stages. Our study aim was
to explore the correlation between tumor epithelial-to-mesenchymal transition
(EMT) and patient survival. Renal biopsies of tumorous and adjacent nontu-
morous tissue were taken with a 16 g needle from our patients (n = 26)
undergoing partial or radical nephrectomy due to ccRCC. RNA sequencing
libraries were generated using Illumina TruSeq Access library preparation
protocol and TruSeq Small RNA library preparation kit. Next generation
sequencing (NGS) was performed on Illumina HiSeq2500. Comparative analy-
sis of matched sample pairs was done using the Bioconductor Limma/voom
R-package. Liquid chromatography-tandem mass spectrometry and immuno-
histochemistry were applied to measure and visualize protein abundance. We
detected an increased generic EMT transcript score in ccRCC. Gene expression
analysis showed augmented abundance of AXL and MMP14, as well as down-
regulated expression of KL (klotho). Moreover, microRNA analyses demon-
strated a positive expression correlation of miR-34a and its targets MMP14
and AXL. Survival analysis based on a subset of genes from our list EMT-
related genes in a publicly available dataset showed that the EMT genes corre-
lated with ccRCC patient survival. Several of these genes also play a known
role in fibrosis. Accordingly, recently published classifiers of solid organ fibro-
sis correctly identified EMT-affected tumor samples and were correlated with
patient survival. EMT in ccRCC linked to fibrosis is associated with worse sur-
vival and may represent a target for novel therapeutic interventions.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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Introduction
Renal cell carcinoma, also named renal cell adenocarci-
noma, comprises over 80% of primary renal neoplasms
and is among the ten most frequent forms of cancer in
both men and women (Escudier et al. 2016). Clear cell
renal cell carcinoma (ccRCC) represents the most com-
mon (75–85%) form of renal cell carcinomas and is one
of the most lethal genitourinary cancers. Up to a quarter
of patients display distal metastases or advanced regional
disease at the time of presentation and diagnosis.
Morbidity and mortality of advanced ccRCC is high.
Patients with metastatic ccRCC have a 5-year survival of
between 0 and 32% depending upon their risk stage at
time of diagnosis (Escudier et al. 2016). Therefore, the
identification of new mechanisms, biomarkers and related
treatment targets is of great clinical importance for the
management of ccRCC patients.
Our study focuses on the role of epithelial-to-mesench-
ymal transition (EMT) as one of the initial steps toward
the development of fibrosis, and its potential role in
ccRCC. EMT was first described in the 1980s and is phys-
iologically involved in embryogenesis and in pathological
states, such as development of solid organ fibrosis. EMT
is also associated with tumor invasiveness and distal
metastasis (Gjerdrum et al. 2010; Thiery and Lim 2013;
Lovisa et al. 2015; Piva et al. 2016). EMT defines a pro-
cess, where epithelial cells lose their polarity and barrier
integrity and develop a mesenchymal phenotype, which
includes acquired motility. The acquisition of a mes-
enchymal phenotype in part results from the loss of inter-
cellular junctions and from the reorganization of the
actin cytoskeleton to promote migratory behavior (Thiery
and Sleeman 2006; Kidd et al. 2014). Moreover, EMT
renders cancer cells immune-evasive, drug-resistant, and
contributes to the metastatic cascade (Gjerdrum et al.
2010; Fleuren et al. 2014; Reichl et al. 2015; Zhou et al.
2016b). Thus, activation of EMT is a key process that
promotes local invasion, distal metastasis and drug resis-
tance (Gjerdrum et al. 2010). The identification of the
signaling pathways leading to activation of EMT programs
in cancer should provide new insights into cell plasticity
and therapeutic interventions to optimize health care
delivery. Accordingly, EMT has been shown to play a key
role in the progression of both experimental and human
ccRCC (Yu et al. 2015; Piva et al. 2016; Zhou et al.
2016a).
Different molecules and pathways are associated with
the control of EMT, including transforming growth factor
b (TGFb), fibroblast growth factor (FGF), and klotho
(KL) (Thiery and Sleeman 2006; Doi et al. 2011; Grande
et al. 2015). Known EMT triggers are cytokines such as
TGFb and FGF. TGFb and EGF lead to the activation of
transcriptional factors including SNAIL1 and SNAIL2,
TWIST, ZEB1 and ZEB2 which induce gene expression
patterns favoring EMT development (Lamouille et al.
2014; Grande et al. 2015; Lovisa et al. 2015). As a conse-
quence, down-regulation of E-cadherin (CDH1), an
epithelial marker involved in intercellular connections,
and up-regulation of vimentin (VIM), a mesenchymal
marker, are typically observed in EMT. However, carci-
noma cells can adopt multiple intermediate, possibly
metastable stages (Nieto et al. 2016).
The transcription factors SNAIL1, ZEB1, and ZEB2
induce the expression of matrix metalloproteinases
(MMPs). MMPs are crucial mediators of cancer EMT as
they influence tumor behavior, especially invasiveness, by
proteolysis of extracellular matrix (ECM) (Kalluri and
Neilson 2003; Jorda et al. 2005; Thiery et al. 2009;
Mahimkar et al. 2011; Lamouille et al. 2014). The princi-
pal MMPs involved in cancer are MMP2, MMP9 and
most notably MMP14 (Seiki et al. 2003; Mahimkar et al.
2011; Lamouille et al. 2014). Increased expression of
MMP2 and MMP9 is associated with poor prognosis in
ccRCC (Kallakury et al. 2001; Chen et al. 2014; Mikami
et al. 2016). Expression of MMP14, also known as
MT1MMP, correlates with the extent of renal epithelial
tumor EMT and invasive capacity (Mahimkar et al. 2011).
Mutation or hypermethylation-induced inactivation of the
tumor suppressor gene Von-Hippel-Lindau (VHL)
increases activity of the mitogen-activated protein kinase
(MEK) protein. Sustained activation of the MEK1 module
leads to the higher expression of MMP14 and is related to
the degree of EMT. In accordance, the activity of the
MEK1/MMP14 signaling module is highly correlated with
tumor nuclear grade and invasiveness of ccRCC (Mahim-
kar et al. 2011).
The AXL receptor tyrosine kinase, with its main ligand
growth arrest-specific 6 (GAS6), is emerging as another
important promotor and regulator of EMT (Gjerdrum
et al. 2010). High expression of AXL and its pathway can
be detected in various cancers including acute myeloid
leukemia, prostate, breast, lung, and skin cancers (Axelrod
and Pienta 2014). AXL, along with MERTK and TYRO3,
is a member of the TAM receptor family (Korshunov
2012). Binding of GAS6 leads to the oligomerization of
AXL with tyrosine phosphorylation and activation of a
down-stream signaling cascade (Jorda et al. 2005). AXL-
mediated EMT is known to be important for ccRCC pro-
gression (Yu et al. 2015; Zhou et al. 2016b).
Both AXL and MMP14 mRNA’s are targeted by miR-
34a, which represents an important microRNA in cancer
development (Jia et al. 2014; Li et al. 2015). MiR-34a rep-
resents a mediator of p53-dependent tumor inhibition,
and its low expression correlates with worse prognosis in
several cancers (Fritz et al. 2015).
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The aim of this study, which includes mRNA and to a
more limited extent miRNA sequencing and proteomics,
is to describe in detail the dysregulation of EMT and its
related genes in a cohort of ccRCC patients and to deter-
mine if the results have prognostic value in other patient
cohorts.
Methods
Patients and renal tissues
This study includes renal tissue from 26 patients with
ccRCC who attended Haukeland University Hospital in
Bergen Norway and underwent partial or radical (full)
nephrectomy from November 2013 until September 2015,
as published previously (Eikrem et al. 2016a,b). Two
additional patients were excluded because of a mixture of
carcinoma and normal tissue in the respective biopsies.
Renal core biopsies of tumorous and adjacent noncancer-
ous normal tissue, as judged by histopathology, were
taken with a 16 g needle perioperatively. Core biopsies of
tumorous and adjacent non-tumorous tissues were forma-
lin-fixed and paraffin-embedded (FFPE), as described
(Eikrem et al. 2016a).
Patients (10 females and 16 males) had a mean age of
57.4  12 years (58.2  11 years for females and
56.9  12.9 years for males). All patients had tumor-
negative lymph nodes and no metastases. Detailed patient
characteristics are summarized in Table 1.
The regional Ethics Committee of Western Norway
approved our studies (REC West no. 78/05). All partici-
pants provided written consent as requested by our Ethics
Committee.
RNA extraction and quality assessment for
next generation sequencing
Total RNA was extracted from FFPE stored kidney core
biopsies using the miRNeasy FFPE kit (Qiagen) as
reported (Eikrem et al. 2016a; Landolt et al. 2016).
Table 1. Patient characteristics.
Patient
ID
Age
(year) Gender
BMI
(kg/m2)
Nephrectomy
type
eGFR
(mL/min/1.73 m2) TNM-stage
Fuhrmann
grade (1–3)
Cancer
stage (1–4)
Leibovich
score (0–11)
Sample
usage
9 70 Male 24 Partial >60 pT1AcN0cM0 2 1 0 R
10 69 Male 34 Partial >60 pT3AcN0cM0 2 2 4 R
11 37 Male 27 Partial >60 pT1AcN0cM0 2 1 0 R
13 63 Male 24 Full 40 pT3AcN0cM0 4 2 8 R
15 68 Male 28 Partial >60 pT1AcN0cM0 2 1 0 R
18 78 Male 27 Full 47 pT3AcN0cM0 2 2 4 R, P
19 71 Female 22 Full >60 pT2aN0cM0 1 2 4 R
21 53 Female 25 Full 55 pT1 BcN0cM0 2 1 2 R, P
22 49 Male 25 Partial >60 pT1 BcN0cM0 2 1 3 R, P
27 46 Male 31 Full >60 pT2BcN0cM0 3 2 5 R, P
29 54 Female 29 Partial >60 pT1AcN0cM0 2 1 0 R, P
31 67 Male 25 Partial >60 pT1AcN0cM0 1 1 0 R, P
32 36 Male 23 Partial >60 pT1AcN0cM0 3 1 1 R
33 48 Male 28 Partial >60 pT1AcN0cM0 1 1 0 R, P
39 71 Male 25 Full 59 pT3AcN0cM0 4 3 8 R, M, P
44 74 Female 23 Full >60 pT3AcN0cM0 2 3 4 R, M, P
46 53 Female 24 Partial >60 pT1AcN0cM0 1 1 0 R, M, P
50 72 Female 19 Full >60 pT1 BcN0cM0 2 1 3 R, M
53 46 Female 44 Full >60 pT2AcN0cM0 2 2 3 R, M, P
55 44 Female 23 Full >60 pT3AcN0cM0 3 3 5 R, M
57 63 Female 28 Full >60 pT1AcN0cM0 2 1 0 R, M
59 52 Female 29 Partial >60 pT1AcN0cM0 2 1 0 R, M
63a 55 Male 28 Partial >60 pT1AcN0cM0 3 1 1 R, M
63b 44 Male 20 Partial >60 pT1AcN0cM0 2 1 0 R, M
64 52 Male 26 Full >60 pT1 BcN0cM0 3 1 4 R, M
65 57 Male 24 Full >60 pT2AcN0cM0 3 2 R, M
Characteristic patient (n = 26) features at the time of surgery. eGFR was calculated with the MDRD formula. Full nephrectomy is equivalent to
radical nephrectomy. The “Cancer Stage” was determined based on the European Association of Urology (EAU) Guidelines on renal cell carci-
noma: 2014 update (Gjerdrum et al. 2010). Leibovich score: 1 = low risk, 2 = intermediate risk, 3 = high risk (Leibovich et al. 2003). Sample
usage: “R”, mRNA sequencing; “M”, microRNA (miR) sequencing; “P” , proteomics.
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Quality and quantity of extracted RNA were assessed
using the Agilent RNA 6000 Nano Kit on a 2100 Bioana-
lyzer instrument (Agilent Technologies, Santa Clara, CA).
We calculated the DV200 value (the percentage of RNA
fragments longer than 200 nucleotides) as a measure to
estimate the quality of RNA necessary for sequencing
(Huang et al. 2015; Eikrem et al. 2016a; Landolt et al.
2016). The mean DV200 values (95% CI) of the samples
of 26 patients (with each tumorous and non-tumorous
FFPE samples) were 65.7% (58.9–72.4%); a minimum
level of 30% is required for sequencing (Huang et al.
2015; Eikrem et al. 2016a).
RNA library preparation and sequencing
RNA sequencing libraries were prepared using the TruSeq
RNA Access library kit (Illumina, Inc., San Diego, CA,
USA) for mRNA sequencing (n = all 26 patients) or the
TruSeq Small RNA Library Preparation Kits (Illumina
Inc, San Diego, CA) for miRNA sequencing (subgroup of
n = 12 patients, as shown in Table 1) according to the
manufacturer‘s protocol. RNA sequencing was performed
on a HiSeq2500 instrument (Illumina, San Diego, CA)
according to the manufacturer’s protocol and as described
previously (Eikrem et al. 2016a,b).
Sequencing data are available via Gene Expression
Omnibus, https://www.ncbi.nlm.nih.gov/geo/; GSE76207
and GSE82122.
Bioinformatics of RNA sequencing
Assembly of reads and alignment of the contigs to the
Human Genome Assembly GRCh38 were guided by
Tophat and Bowtie. For the mRNA expression data of 52
samples from 26 patients, an empirical expression filter
was applied, which left genes with at least 3 counts per
million (cpm) in at least 19 samples.
A list of 483 EMT genes was compiled from three pub-
lically available sources (http://dbemt.bioinfo-minzhao.
org; (Chen et al. 2014; Groger et al. 2012)), and supple-
mented by the addition of genes involved in EMT based
on our own study interest, as described below.
For the microRNA expression data of 22 samples from
11 patients, an empirical expression filter was applied,
which left microRNA species with at least 3 cpm in at
least nine samples.
Comparative analysis was done using the voom/Limma
R-package. Differential gene expression with a moderated
paired t-test was defined as Benjamini-Hochberg adjusted
P ≤ 0.05, and an absolute fold change of ≥2.
Survival analyses using mRNA or microRNA were per-
formed using two tools, (http://bioinformatica.mty.itesm.
mx:8080/Biomatec/SurvivaX.jsp), and SurvMicro (http://
bioinformatica.mty.itesm.mx:8080/Biomatec/Survmicro.
jsp), respectively. For the mRNA analysis we used 468
samples from the TCGA ccRCC dataset; for the micro-
RNA analysis we employed 217 HiSeq samples from
TCGA. Further data analysis and visualization was per-
formed with JMP Pro 11 (www.sas.com), and Graphpad
version 6 and 7 (www.graphpad.com).
Classifier analysis was performed as recently published
(Rodder et al. 2009, 2011). The classifier consisted of a
panel of metzincins and related genes (MARGS), and the
algorithm linear discriminant analysis. The analysis was
performed in JMP Pro 11 (www.sas.com). The ccRCC
dataset was treated as the test set, as the classifiers had
been trained already in other datasets (Rodder et al. 2009,
2011).
Transcriptomic EMT score
A generic EMT score was computed for each of the RNA-
seq samples using a method described previously (Tan
et al. 2014). Briefly, using an EMT signature derived from
bladder, breast, colorectal, lung, gastric, and ovarian can-
cers, a two-sample Kolmogorov-Smirnov test was per-
formed to assess the extent of EMT enrichment. A high
enrichment score of the EMT signature indicate a sample
to be more mesenchymal-like, whereas a low enrichment
score indicates a sample to be more epithelial-like.
Proteomics
This investigation was performed in a subgroup of
patients (n = 11) from our total subject cohort (n = 26),
as indicated in Table 1. Protein and peptide extraction:
After deparaffinization with xylene, tissue sections
(10 lm) were lysed by suspension in 20 lL lysis solution
[0.1 mol/L Tris-HCl pH 8, 0.1 mol/L dithiothreitol
(DTT), 4% sodium dodecyl sulphate (SDS)] and heated
at 99°C for 60 min. Filter aided sample preparation
(FASP) was performed as described (Wisniewski 2013).
Eluted peptides were desalted and cleaned using Oasis
HLB lElution plates (Waters, Milford, Mass.), and pro-
tein concentrations were measured by A280 using Nano-
Drop (Thermo Scientific). The samples were analyzed
with a 180 min LC gradient on a Q-Exactive HF (Thermo
Scientific) connected to a Dionex Ultimate NCR-3500RS
LC system.
We used label-free protein quantification: Raw data
from the MS was processed using Progenesis LC-MS soft-
ware (version 4.0, Nonlinear Dynamics, UK) with default
settings. Features were searched with searchGUI (version
2.2.2) and PeptideShaker (version 1.2.2) applying the
UniprotKB/SwissProt human database (downloaded from
Uniprot August 2015, 20,197 entries). Precursor mass
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tolerance was set at 10 parts per million, and product
mass tolerance at 0.5 Dalton. Carbamidomethylation of
cysteines and oxidation of methionines were set as fixed
and variable modifications, respectively. Two missed
cleavages were allowed, and false discovery rate was set at
1%.
Immunohistochemistry
Immunohistochemistry (IHC) of AXL, CDH1, MMP14,
and VIM was performed on 3 and 4 lm thick FFPE sec-
tions following standard methodology. The following pri-
mary antibodies were used: AXL (1H12, BerGenBio AS,
Bergen, Norway,(Nalwoga et al. 2016)), CDH1 (mono-
clonal mouse anti-E-cadherin, clone NHC-38, Dako, Agi-
lent Technologies, Santa Clara, CA, USA, catalogue
number: MA5-12547), MMP14 (monoclonal rabbit anti-
MMP14, Abcam, Cambridge, UK, catalogue number:
EP1264Y) and VIM (monoclonal mouse anti-vimentin,
clone V9, Dako, Agilent Technologies, Santa Clara, CA,
USA, catalogue number: M072529-2). Slides were incu-
bated with the specified antibodies, such as AXL 1 lg/
mL, CDH1 1:200 and VIM 1:1000, for 1 h at room tem-
perature. MMP14 antibodies 1:1200 were applied over-
night at 4°C. Sections were counterstained with
hematoxylin (Dako, catalogu number: CS70030-2), then
dehydrated and cover-slipped.
Results
The hypothesis underlying this study was that a transition
from normal renal structure to ccRCC is characterized by
EMT. To test this hypothesis and to characterize the
extent of EMT in ccRCC, we determined gene expression
levels of EMT genes from ccRCC patient biopsies and
compared them to levels in matched, adjacent, normal
tissue. Patient characteristics are summarized in Table 1.
Importantly, no patient had signs of metastases.
Increased generic EMT score in renal cell
carcinoma
We first assessed whether gene expression changes could
be used to reflect the degree of EMT in the samples. To
that end, we employed an EMT score calculation, which
is based on the enrichment score of 315 genes, as previ-
ously described (Tan et al. 2014). A higher EMT score
indicates greater mesenchymal characteristics. Accord-
ingly, a lower EMT score reflects a more epithelial-like
phenotype.
Figure 1 shows that the EMT score of normal non-
cancerous kidney tissue samples indicates a relatively mes-
enchymal-like value. However, in 25 of 26 sample pairs,
the EMT score values were significantly higher in ccRCC
(TU) samples as compared to the matched normal (NO)
sample. Importantly, there was neither a difference com-
paring normal, non-cancer tissues obtained from partial
versus radical nephrectomy nor effects of age, sex or can-
cer stage on the degree of EMT score (data not shown).
The data also show that in our dataset EMT score
alone cannot be used as indicator of ccRCC, since the
individual scores of NO and TU samples are not clearly
separated. The value of this analysis lies in the increase of
the EMT score from NO to the respective matched TU
sample.
Alterations in EMT gene expression distinct
renal cell carcinoma from normal tissue and
correlate with cancer stage
We have investigated alterations in the gene expression
pattern on the mRNA and on the miRNA level as well as
to a lesser degree on the protein level.
Analysis of mRNA abundances
We compiled a list of EMT-related genes from three pub-
lic sources and our own data. The study by Chen et al.
(2014) used microarray data to identify 46 EMT genes in
normal and primary ccRCC. Gr€oger and colleagues per-
formed a meta-analysis of cancer gene expression studies
in primary cell cultures and concluded on a core set of
131 EMT genes with relevance in tumor progression
(Groger et al. 2012). Further we extracted 357 genes from
the dbEMT database (http://dbemt.bioinfo-minzhao.org/,
(Zhao et al. 2015). Surprisingly, only six genes were com-
mon to all three datasets (CDH1, CDH2, FN, MMP2,
VIM, and ZEB1). The inclusion of other relevant genes,
such as GAS6 and AKT3, resulted in a gene list
Figure 1. Epithelial-Mesenchymal Transition (EMT) score of 26
adjacent normal-tumor pairs from renal clear cell carcinoma
patients. P-value shown is computed by matched-pairs two-sided
Wilcoxon signed rank test. NO, normal, non-carcinoma tissues; TU,
respective ccRCC samples.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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comprising 483 EMT-related genes implicated in ccRCC.
In the gene expression analysis of matched ccRCC and
adjacent normal biopsy samples from 26 patients (n = 52
samples), 399 of these 483 EMT-related genes (83%)
passed the expression filter (see Material and Methods)
and were retained in the analysis. Of those 399 genes, 137
were differentially expressed (absolute logFC>1, adjusted
P- ≤ 0.05). Of the 315 genes used in the EMT score anal-
ysis, 71 were included in the list of 399 detected EMT-
related genes, and 39 were differentially expressed.
Unsupervised hierarchical cluster analysis illustrates
how the normalized expression values of the 137 mRNAs
led to the formation of two distinct clusters of samples,
consisting of normal and tumor samples, respectively
(Fig. 2A). Genes with the largest fold changes in tumor
tissue compared to normal tissue included EGF and
TNFAIP6. Scatterplots for selected genes are shown in
Figure 2B.
Twenty genes with the largest absolute fold change of
mRNA abundance and smallest P-values are shown in
Table 2. From this list, three genes were detected
and confirmed by proteomics, as described below.
Other upregulated, important EMT-related genes, which
were not present in the list of the top 20 genes, were
SNAI1, TGFb1, and CTNNB1 (b-catenin); data not
shown.
To analyze the contribution of the 137 variables (differ-
entially expressed genes) toward explaining the data struc-
ture (i.e., variance), we applied principal component
analysis (PCA), as depicted in Figure 3. The normalized
expression data for the differentially expressed mRNA
explained 58.7% of the variance in principal component 1
(PC1) and leads to a visual separation of the normal and
the tumor samples (Fig. 3A). The biplot in Figure 3B rep-
resents both the samples (illustrated as black points) and
vectors of the variable contribution (or loadings, in red)
to represent the data structure. As in the PCA, the axes of
the biplot are the principal components. Vectors that
point in the same direction correspond to variables that
have similar response profiles. The loadings represent cor-
relations between the input variables and the principal
component scores; they can be negative or positive.
Extraction of the loadings of the variables for PC1, and
ranking them by the largest to smallest absolute value
identifies the mRNA variables with the largest contribu-
tion to PC1, which explains the difference between
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Figure 2. RNA sequencing data analysis. (A) Unsupervised hierarchical cluster analysis with 137 differentially expressed EMT-related mRNA. The
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levels of selected genes.
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normal and tumor samples. As shown in the list of ten
mRNA with largest absolute loadings for PC1 (Fig. 3C),
ITGA5 has the largest contribution, AXL and MMP14
rank 6th and 9th, respectively, indicating their importance
in explaining the data structure, similarity and difference
between samples.
Next, we analyzed whether any mRNA expression pro-
files were correlated with cancer stage, as described by us
and others (von Roemeling et al. 2014; Eikrem et al.
2016a). We correlated the log2 cpm expression values of
the EMT genes, which were obtained from the LIMMA/
VOOM analysis in R Bioconductor, to the cancer stage
applying a bivariate polynomial fitting algorithm. CAV1
had the largest absolute correlation, followed by VIM,
IGFBP3, and ITGA1. Interestingly, the expression levels
did not increase from the stage 2 to stage 3, and in
some cases even decreased. These results are depicted in
Figure 4.
Figure 5 summarizes the expression data obtained for
MMP14. Besides RNA-sequencing, we applied proteomics,
and immunohistochemistry. Using these three technolo-
gies, we could confirm RNA abundance as well as protein
abundance of MMP14, revealing an approximate twofold
higher average expression level in ccRCC tumor speci-
mens compared to normal samples. Note, only one
patient showed an inexplicable decrease on MMP14 in
ccRCC as analyzed by proteomics.
Applying proteomics and IHC, we also detected
increased abundance of protein of AXL, and VIM, in
ccRCC, and decreased abundance of CDH1, thereby sup-
porting RNA sequencing data, as depicted in Figure 6A
and B. In addition, Figure 6A indicates that there could
be some stromal cells detectable next to CDH1-positive
tubules, which may explain in part the relatively high
EMT values of some carcinoma-adjacent normal kidney
samples (Fig. 1).
Analysis of microRNA expression
Expanding our analysis of gene expression data to the
analysis of those microRNAs with involvement in EMT,
we sequenced microRNAs from 12 ccRCC samples and
the 12 respective normal specimens from our patient
cohort, followed by pairwise comparison of their abun-
dance as done for mRNA. Most of the patient material is
shared between the microRNA and the mRNA studies.
MicroRNAs associated with EMT were identified from
the literature (Zhang and Ma 2012; Zaravinos 2015). The
respective results are shown in Table 3. Mir-34a, which
targets AXL and MMP14 (Jia et al. 2014; Li et al. 2015) is
Table 2. Differentially expressed genes.
ENSEMBL_ID Symbol
RNAseq
t P value adj P value
Proteomics
log FC
(TU/NO)
abs ClogFC
(TU/NO)
log FC
(TU/NO) P value
adj
P value
ENSG00000138798 EGF 6.09 6.09 —16.69 6.10E-16 9.96E-14
ENSG00000123610 TNFAIP6 5.91 5.91 16.86 4.72E-16 8.02E-14
ENSG00000171004 HS6ST2 5.61 5.61 —12.87 3.53E-13 1.06E-11
ENSG00000135374 ELF5 5.54 5.54 —11.52 4.77E-12 8.54E-11
ENSG00000159263 SIM2 5.29 5.29 —10.55 3.45E-11 4.44E-10
ENSG00000198910 L1CAM 4.34 4.34 —13.61 9.37E-14 3.85E-12 !0.43 8.18E!03 2.77E!02
ENSG00000136943 CTSL2 3.94 3.94 —11.14 1.02E-11 1.59E-10
ENSG00000137648 TMPRSS4 3.60 3.60 6.34 7.96E-07 2.90E-06
ENSG00000107485 GATA3 3.59 3.59 —18.14 7.30E-17 1.87E-14
ENSG00000198780 FAM169A 3.45 3.45 —12.67 5.17E-13 1.43E-11
ENSG00000146674 IGFBP3 3.38 3.38 19.75 8.31E-18 4.18E-15 3.26 1.23E-03 6.70E-03
ENSG00000113083 LOX 3.35 3.35 11.59 4.09E-12 7.52E-11
ENSG00000104413 ESRP1 2.99 2.99 6.16 1.28E-06 4.48E-06
ENSG00000106541 AGR2 2.97 2.97 3.76 8.03E-04 1.60E-03
ENSG00000184937 WT1 2.97 2.97 8.16 7.88E-09 4.72E-08
ENSG00000113578 FGF1 2.95 2.95 9.64 2.51E-10 2.33E-09
ENSG00000118526 TCF21 2.85 2.85 9.10 8.57E-10 6.83E-09
ENSG00000101144 BMP7 2.75 2.75 3.87 6.05E-04 1.24E-03
ENSG00000112715 VEGFA 2.72 2.72 14.91 1.01E-14 7.68E-13
ENSG00000038427 VCAN 2.72 2.72 7.92 1.41E-08 7.97E-08 3.01 3.90E-05 6.15E-04
Top 20 differentially expressed EMT genes (sorted by decreasing absolute log2fold change in mRNA abundance) and available proteomics
results.
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one of the most significantly affected microRNAs. The
expression levels of these three microRNA and mRNA
species are found to be strongly positively correlated in
our datasets (Fig. 7).
Expression of tumor EMT-genes and also of
fibrosis-related genes correlates with patient
survival
However, while mir-34a is highly expressed in high-risk
ccRCC groups, it did not correlate with patient survival
in 217 ccRCC samples (see Material and Methods; data
not shown). MMP14 and AXL on the other hand are sig-
nificantly associated with patient survival, being higher
expressed in high-risk groups within 468 human ccRCC
samples (Fig. 8A–D).
KL (klotho) has recently been shown to inhibit TGFb1
and to decrease renal fibrosis and cancer metastasis (Doi
et al. 2011). As KL was differentially expressed in our
dataset (fold change TU/NO -3.43, P-value 2.15E-07), we
tested the effect on patient survival on 468 samples of the
TCGA clear cell carcinoma dataset implemented (Material
and Methods). In accordance with the literature, lower
expression levels of KL indicated lower patient survival
(Risk Group Hazard Ratio 3.61, P-value 4.41E-14), as
shown in Figure 8E–F.
Finally, we evaluated combinations of differentially
expressed genes. A set of four collagen genes with an
expression very tightly correlated across the samples
(COL1A1, COL1A2, COL3A1, and COL5A1; correlation
0.8  0.025) outperformed MMP14 and AXL (Risk
Group Hazard Ratio 3.19, P-value 1.11E-11). All collagen
genes are higher expressed in high-risk group and corre-
lated with patient survival (Figure 9A and B).
Furthermore, we tested various combinations of genes
from the set of 20 genes highest fold changes between
NO and TU (Table 2). A set of 11 genes allowed us to
predict patient survival to a much better degree than any
individual gene we tested (Risk Group Hazard Ratio 4.28,
P-value 1.32E-15), as shown in Figure 9C and D.
The member genes of two gene sets, the collagen-based
set (Fig. 9A and B) and the panel of 11 genes (Fig. 9C
and D), underscore the tight link between EMT and
fibrosis development. Notably, EMT and its intermediate
ENSEMBL_ID Symbol
abs PC1          
loading logFC t PValue adjPVal
ENSG00000161638 ITGA5 0.97 2.12 18.52 4.34E-17 1.31E-14
ENSG00000026025 VIM 0.96 2.41 20.95 1.8E-18 1.62E-15
ENSG00000105974 CAV1 0.94 2.72 20.27 4.2E-18 2.93E-15
ENSG00000076706 MCAM 0.94 2.21 16.97 3.97E-16 7.04E-14
ENSG00000164050 PLXNB1 0.94 –1.82 –17.00 3.8E-16 6.92E-14
ENSG00000167601 AXL 0.93 1.61 14.50 1.99E-14 1.22E-12
ENSG00000113140 SPARC 0.93 2.03 14.77 1.27E-14 9E-13
ENSG00000119888 EPCAM 0.93 –2.65 –16.42 9.15E-16 1.32E-13
ENSG00000157227 MMP14 0.93 1.46 14.70 1.42E-14 9.53E-13
ENSG00000146674 IGFBP3 0.92 3.38 19.75 8.31E-18 4.18E-15
–20
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Figure 3. Principal component analysis with differentially expressed EMT genes. (A) Principal component analysis (PCA) with 137 differentially
expressed EMT-mRNA. The sample groups “healthy” (normal, NO) and “ccRCC” (tumor, TU) are separated along the principal component 1
(PC1). Ellipsoids indicate the 95th percentile of data points per group. (B) The biplot demonstrates the samples as dots, and the contribution of
each variable toward the explanation of the variance of the data as red arrows. Each arrow can be attributed a value, the loading score. (C)
Ten mRNA with the largest absolute loading scores. ITGA5, AXL and MMP14 are among the mRNAs with the largest loading scores.
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states have recently been identified as key promoters of
organ fibrosis (Nieto et al. 2016). Amongst the genes of
the two sets, especially collagens 1 and 3, but also 5 can
be augmented in solid organ fibrosis, including the kidney
(Mak et al. 2016). Moreover, the EMT drivers TGFb and
epithelial growth factor (EGF) are also linked to the pro-
motion of fibrosis development (Kok et al. 2014; Grande
et al. 2015).
Therefore, in a subsequent step, we applied our previ-
ously described fibrosis classifier in humans, which is
based on metzincins and related genes (MARGS). The
classifier was successfully applied in renal allografts (clas-
sifier with 19 MARGS genes) and in solid human organ
fibrosis (classifier with 10 of the 19 MARGS genes), (Rod-
der et al. 2009, 2011). This fibrosis classifier was also vali-
dated across species in rat fibrosis models (Marti et al.
2014, 2016). Both models classified all samples correctly
into normal and ccRCC samples (Fig. 10) despite the fact
that the majority of our tumor samples (n = 24) had
areas of intra-tumor stroma and/or evidence of fibrosis,
as judged by light microscopy (data not shown).
We also tested the performance of the MARGS classi-
fiers with respect to the patient survival. The 19-gene
panel classifier had a Risk Group Hazard Ratio of 3.6
(P-value 4E-12), and the 10-gene MARGS classifier of
solid organ fibrosis a Risk Group Hazard Ratio of 2.97
(P -value 7.3E-9).
Discussion
This study provides additional evidence for the patho-
physiologic and prognostic role of EMT gene expression
in the development of ccRCC. To the best of our knowl-
edge, this is the first report combining mRNA/miRNA
next generation sequencing with proteomics in FFPE
ccRCC tissues, and linking results to fibrosis. Firstly, we
observed an increased EMT score in ccRCC. Thereafter,
we have analyzed several individual genes and finally, we
have obtained two prognostic EMT-related gene sets con-
sisting of four and eleven genes, respectively. Many of
these genes are also linked to fibrosis development.
Numerous genes are involved in EMT and their selec-
tion for analysis ultimately remains incomplete. We
decided to first use an established, generic EMT score for
an initial EMT screening, as published by members of
our group (Tan et al. 2014). The respective results indi-
cated that our dataset can be used to address whether
EMT-related genes play a role in ccRCC. It also
Figure 4. Bivariate polynomial regression of the mRNA abundance and cancer stage. CAV1, VIM, IGFBP3, and ITGA5 were the mRNAs with
strongest regression. The expression level for all mRNAs declined in samples with the highest tumor stage. The dark red area is the confidence
limit for the expected fitted mean, the light red area displays the confidence limits for the individual predicted value. The confidence limits
reflect variation in the error and variation in the parameter estimates. Cancer stage (see also Table 1) is indicated as numerical values from 1 to
3, with 0 indicating tumor-unaffected status corresponding to the respective noncancerous normal tissues.
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Figure 6. Representative immunohistochemistry (IHC) analyses of protein abundance by proteomics of three genes involved in EMT. Protein
level of AXL and VIM were increased in ccRCC, while CDH1 protein was decreased (A). IHC results are supported by proteomics data for VIM
and CDH1 (B). AXL protein was not detected in the proteomics dataset.
Figure 5. Detection of expression changes of MMP14 in ccRCC. Top left (“RNA-seq”): MMP14 mRNA is about 1.46-logfold increased in ccRCC.
Matched normal samples from the same patients are connected by a line to illustrate the expression change. Top right (“Proteomics”): Increased
abundance of MMP14 protein in ccRCC. Two samples, patients 27 and 29, showed decrease in MMP14 expression in ccRCC. In RNA sequencing
data, MMP14 mRNA levels were increased in ccRCC also for these two patients. Matched normal and ccRCC samples from the same patient are
connected to illustrate the expression change. Bottom (“IHC”): Representative immunohistochemistry (IHC) results showing the increased
detection of MMP14 epitope in an ccRCC sample (“TU”) in comparison to the matched healthy (“NO”) sample from the same patient.
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demonstrates that samples adjacent to tumor and histo-
logically cancer-negative can display a gene expression
pattern consistent certain degree of EMT development.
Thereafter, detailed gene expression analyses were pri-
marily based on the dbEMT database containing 357
genes, as this is a curated gene list based on experimental
evidence extracted manually from respective publications.
EMT indeed plays an important role in renal cell carci-
noma, which supports the ultimate goal and rationale for
EMT-directed therapeutic strategies for these patients
(Piva et al. 2016). Our comprehensive approach is best
exemplified by the description of the up-regulated
MMP14 by investigations on all levels, such as mRNA
sequencing, proteomics, and immunohistochemistry, as
well as by the analysis of its regulator miR-34a. Notably,
MMP14 is - together with AXL, caveolin 1 (CAV1) and
ITGA5 - among the top genes contributing to the differ-
entiation of cancer from normal tissue. Expression levels
of miR-34a and target genes AXL and MMP14 are closely
correlated among each other and clearly separate tumor
from adjacent normal tissue.
The integrin ITGA5 is expressed by renal carcinoma
cells but its exact function remains to be determined
(Poplawski et al. 2017). Based on our findings, this mole-
cule warrants further exploration. CAV1 expression
displayed the largest absolute correlation with tumor
stage, followed by VIM, IGFBP3, and ITGA1. CAV1 has
not been described in the context of EMT in ccRCC, but
it is over-expressed in hepatocellular carcinoma and pro-
motes cancer cell invasion via inducing EMT (Gai et al.
2014). Accordingly, increased expression of CAV1 can
predict a poor prognosis of patients with ccRCC (Steffens
et al. 2011).
Our results have implications for prognosis of ccRCC.
Higher MMP14 and AXL mRNA levels are associated with
lower patient survival. Nevertheless, their common regula-
tor mir-34a, although highly produced in high-risk
ccRCC, does not have prognostic value in terms of
patient survival. In accordance with our results, AXL inhi-
bition represents an emerging treatment option in oncol-
ogy (Feneyrolles et al. 2014). A selective small molecule
Axl kinase inhibitor (BGB324) is currently in Phase II
clinical trials for acute myeloid leukemia, melanoma and
non-small cell lung cancer. AXL inhibition in experimen-
tal ccRCC models is beneficial indicating a new therapeu-
tic option (Yu et al. 2015).
AXL and miR-34a are engaged in a complex auto-regu-
lation circuit, which involves targeting of AXL by miR-
34a, while at the same time AXL overexpression leads to
increased expression of miR-34a via ELK1 (Cho et al.
Figure 7. Correlation of expression levels of miR-34a and target genes AXL and MMP14. Pearson correlation of expression levels of miR-34a
and the target genes AXL (A) and MMP14 (B), of AXL and MMP14 (C), and all mir-34a and AXL and MMP14 (D). Red dots indicate normal
samples, blue dots ccRCC tumor samples. Ellipsoids indicate the 95th percentile of data points per group.
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2016). These data may help explain the concordant
up-regulation of AXL and miR-34a in our datasets.
Contrary to our data, miR-34 expression levels did not
correlate to AXL mRNA abundance in a previous ccRCC
investigation (Fritz et al. 2015). We do not have a clear
explanation for this discrepancy beyond the known
ccRCC heterogeneity. However, in that study, levels of
miR-34a were also increased in ccRCC but not associated
with patient outcome, as it is the case for the present
investigation (Fritz et al. 2015).
MMP14 represents an increasingly recognized but com-
plex mediator of EMT and ccRCC. MMP14 is a known
target of miR-34a (Jia et al. 2014). In our analysis, we
observe positive correlation between the expression levels
of MMP14 and miR-34a. This could be explained by the
fact that MMP14 is not exclusively regulated by miR-34a.
In this respect, we must consider the complex network of
miR-34a, which targets several MMPs, including MMP14,
and represses their expression. Higher expression of
another microRNA, miR-21, decreases the expression of
genes coding for TIMPs, such as TIMP3, which then in
turn leads to an increase in invasion-promoting MMPs
(Chernov and Strongin 2011). Importantly, TIMP3 is a
strong inhibitor of MMP14 (Will et al. 1996). Thus, the
MMP regulation pattern is not always linear and unidi-
rectional, but rather includes several checkpoints and
multi-directional paths. Furthermore, control of MMP
expression and activity is remarkably complex, including
at the level of transcription, cellular compartmentaliza-
tion, zymogen activation, and enzyme inhibition (Baker
et al. 2002). MMP14 is also connected to EGFR, since
MMP14 exerts a positive effect on the MEK1/MAPK axis
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through transactivation of the EGFR (Mahimkar et al.
2011). Indeed, EGFR is more than twofold up-regulated
in our ccRCC patient cohort (data not shown). The
expression level of EGFR was previously found to be asso-
ciated with high ccRCC tumor grade and worse prognosis
(Dordevic et al. 2012; Minner et al. 2012).
Klotho (KL) can affect EMT via an interaction with
SNAIL. KL inhibits the PI3K/Akt/GSK3beta/Snail pathway
and decreased KL expression negatively correlates with
ccRCC patient survival in the literature (Zhu et al. 2013;
Gigante et al. 2015). In this respect, Klotho reduces
epithelial-mesenchymal transition and cellular invasion in
renal cell carcinoma (Zhu et al. 2013). Thus, our data
regarding higher KL expression favoring better patient
survival are in accordance with the literature. KL is a gene
encoding a transmembrane protein with anti-aging and
tumor suppression functions (Kuro-o et al. 1997; Xie
et al. 2013; O’Sullivan et al. 2016). In kidneys, KL is nat-
urally present in the proximal tubules, where it increases
phosphaturic processes by modulating the activity of renal
phosphate transporters. Decreased expression levels of KL
are also associated with oxidative stress (O’Sullivan et al.
2016).
Despite observations that many individual genes can be
used at the mRNA level to indicate better or worse prog-
nosis, a combined set comprising several genes may even-
tually give the best predictive value. Accordingly, we have
designed the two novel candidate prognostic marker sets
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representing mRNA abundances of a limited number of
genes to best predict patient survival.
Our results further support a close relationship between
EMT and fibrosis development. Several genes of our
prognostic gene sets, such as collagens and EGF, are
known to bridge EMT and fibrosis. Accordingly, our pre-
viously described MARGS-based fibrosis classifier identi-
fied all our cancer samples correctly and was also
correlated with patient survival. Our results may lead to
better early identification of tissues undergoing EMT and
potentially fibrosis in the onset of ccRCC, and they sup-
port development of new treatment avenues. Nevertheless,
our study has some limitations. The sample size of kidney
biopsies (n = 52) from our ccRCC patient cohort is lim-
ited. Furthermore, there is cellular heterogeneity in the
tumors and adjacent normal tissues. Hence, our results
are a summation of this variability, but reflecting the real
life clinical situation. The issue of cell-specificity regarding
gene expression must be addressed in the future by tissue
microdissection or even by single cell sequencing.
Conclusion
EMT linked to fibrosis represents a prominent feature in
ccRCC, which is closely associated with worse patient sur-
vival. Therefore, EMT-related genes represent a promising
target for future therapeutic interventions.
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